For Biotech & Healthtech CEOs, CSOs and CMOs
Founder-led LinkedIn for CEOs, CSOs and CMOs building investor, KOL and BD visibility
Overview
LinkedIn marketing for biotech and healthtech founders. We help you build a credible, science-first presence that investors, KOLs, advisors and BD partners can find and trust. Every post goes through your own review and approval process before it’s published, and we don’t provide legal or regulatory advice.
Built for life-science founders, pre-clinical to commercial stage
In biotech and healthtech, capital, talent and partnerships move on trust. LinkedIn is where modern trust is built - quietly and continuously.
Investors often look up founders on LinkedIn before a meeting. A clear, scientific, credible profile can help open warm-intro doors.
Many of the clinicians, PIs and operators you want as advisors, SAB members or early hires use LinkedIn. Founders who show up thoughtfully can reach people who might not reply to a cold email.
Pharma BD, hospital innovation leads and payer contacts often use LinkedIn to spot emerging companies before they reach the conference circuit.
Content workflows designed with FDA, EMA, MHRA and HIPAA considerations in mind. Every post goes through your scientific, medical-affairs and compliance review before publishing. Your teams make the final call on what can be said.
Three ways biotech and healthtech companies show up, and what each is best for.
| Dimension | Founder Voice | Corporate Comms | PR Placements |
|---|---|---|---|
| Primary surface | Founder personal profile | Corporate comms / IR page | PR-led media placement |
| Avg time to land | Immediate, ongoing | Slow, quarterly cycles | Weeks per placement |
| Trust signal | Highest - direct from the scientist | Low - feels filtered | Medium - depends on outlet |
| Investor visibility | Continuous, compounds quarterly | Episodic, around milestones | Spiky, around news cycles |
| KOL & talent pull | Direct DMs, warm intros | Recruiting funnel only | Minimal |
| Best for | Capital, talent, partnerships | Regulated disclosures | Milestone news amplification |
Post formats that help build a credible founder presence in regulated life sciences, within your review and approval process.
Post format library
Founder-led LinkedIn looks different from every seat. Here's the outcome each life-science leader cares about.
Capital, credibility, talent
Become the founder investors save, KOLs reply to and operators want to join. A clear LinkedIn presence is increasingly part of how investors and partners research a founder, and it can be a cost-efficient BD channel.
Scientific authority that earns trust
Translate complex science into clear, credible posts that earn respect from peers, attract collaborators and accelerate publication-to-partnership timelines - without dumbing it down.
Reach the KOLs and clinicians you need
Build relationships with PIs, sites and clinical leaders before you need them - for trials, advisory boards and post-market adoption. LinkedIn is where modern medical affairs starts.
Shorter partnership cycles
Pharma BD, payer and provider leads use LinkedIn to source partners. A visible, credible founder voice cuts your time-to-first-meeting in half and warms every outbound conversation.
Every post moves through a defined, documented workflow designed to support your own FDA, EMA, MHRA, HIPAA and SEC-related review requirements. Your medical, regulatory, compliance and legal teams approve what goes out. We don’t provide legal or regulatory advice.
Every topic is classified upfront: scientific/educational, corporate, milestone, or sensitive. Sensitive topics get extra review steps before drafting.
All claims grounded in published data, internal data on file, or peer-reviewed sources. Your CSO or medical affairs lead signs off on scientific framing before legal sees it.
We flag language that may raise pre-approval promotion, off-label or unsupported-efficacy concerns for your reviewers.
For public or pre-IPO companies, we flag items for your IR or legal counsel to review against Reg FD, forward-looking statement and quiet-period requirements.
We don't use identifiable patient information or clinical site identification. Patient stories and testimonials are used only with documented consent.
Post versions and approvals are logged, so there's a record of who approved what and when.
LinkedIn is also where investors form first impressions of founders. We plan for that.
We map a 3–6 month posting arc ahead of your next financing, building science credibility, team narrative and milestone visibility. We don't promote the offering itself, and your counsel reviews the plan.
Forward-looking statement and quiet-period reminders built into the workflow, reviewed by your counsel.
Coordinated visibility around analyst days, JPM week and bank conferences, so relevant investors and analysts see a consistent scientific narrative around key events.
Data readouts, IND clearance, partnerships, hires. Each has a content pattern designed to build confidence without overpromising, reviewed by your counsel for disclosure.
Conference weeks and data readouts are high-visibility moments. We prepare your founder’s presence ahead of time so conversations are warmer when you arrive.
JPM Healthcare Week
Pre-week thesis posts, on-the-ground updates from the founder and a post-week recap, naming meetings only where permissible. Extends a week of meetings into weeks of visibility.
ASCO / AACR / ASH
A pre-conference teaser and abstract-day post that follow each conference's embargo and abstract policies, a KOL tagging approach (with consent) and a clinical-context explainer for non-specialist investors.
Data readouts (Phase 1/2/3)
A pre-readout narrative outline, a readout-day post sequence and a Q&A explainer for investors and partners. Posts go live only after the official disclosure, coordinated with your counsel.
BIO / BioEquity / LSX
Partnering-week presence: who you're meeting (where permissible), the questions you're working on, and a post-conference recap to extend the BD funnel.
IND / regulatory milestones
Standardized milestone post templates for your counsel to review against material-disclosure rules, paired with a founder reflection that humanizes the science.
Press / partnership announcements
A coordinated company-page announcement, amplified by the founder, CSO and CMO, each from their own perspective.
A clear monthly scope for LinkedIn ghostwriting, strategy and reporting, reviewed by your teams.
Ghostwritten founder posts
Reviewed by your medical, regulatory & compliance leads
Founder strategy sessions
Narrative, science storytelling, what to post next
Investor & KOL targeting list
Mapped to your raise, trials and partnership pipeline
Engagement & inbound report
Investor views, KOL connects, BD enquiries, advisor intros
Claims & messaging review
Every post checked for claims discipline and flagged for your regulatory review
Fast async answers
No ticket queues
Pricing on request · 3-month minimum, then month-to-month · No long lock-ins
Founder-led LinkedIn can be a strong channel for investor, KOL and BD visibility.
Trusted by life-science founders, pre-clinical to commercial. Selected outcomes cited below.
Founder reach across investor firms
Series A biotech, 90 days
Warm investor intros in one quarter
Clinical-stage healthtech
KOL & SAB conversations opened
Pre-clinical biotech
*Illustrative figures.
"Three of the lead investors in our Series A told me they followed me on LinkedIn for months before we ever met. The pre-warming was the entire reason the round closed in 5 weeks."
CEO & Co-founder
Clinical-Stage Biotech
"They understand the line between scientific credibility and over-claiming. Every post goes through medical and regulatory review without ever feeling sanitized."
CSO
Oncology Biotech, Pre-IND
"We've had inbound from two pharma BD teams, a payer innovation lead and a clinical PI - all directly from posts. LinkedIn became our cheapest BD channel."
Head of BD
Digital Health, Series B
"I was nervous about posting as a clinician-founder. The coaching gave me a voice I'm actually proud of, and the engagement from peers has been remarkable."
Founder, MD
Diagnostics Startup, Seed
"We attracted two SAB members and a senior commercial hire directly from the founder's LinkedIn presence - people who'd never have replied to a recruiter."
CEO
AI-Drug Discovery, Series A
"The investor list and targeted engagement strategy alone justified the engagement. Our founder is now on the radar of every relevant crossover fund."
Chair of the Board
Medtech, Series B
Programs that compound with founder-led LinkedIn in life sciences.
Everything biotech and healthtech founders ask before investing in LinkedIn.
The frameworks, post formats and review workflows we use to build credible founder presence for biotech and healthtech CEOs.
Inside
"Founders who explain their science clearly give investors and KOLs a reason to follow and reply."
- Digii Ninja
Here is what this service can look like in practice.
A first-time biotech founder raising a round with no network. A credible, science-first LinkedIn presence opened doors to investors who already knew the story.
A CEO whose company was known but whose voice was not. Translating complex science into clear posts made them the person journalists and partners call.
A diagnostics company months from launch. Education-first content built an audience of clinicians ready to adopt on day one.